Healthcare Industry News:  CoNCERT Pharmaceuticals 

Biopharmaceuticals Personnel

 News Release - August 10, 2010

Gregory Miller Joins Concert Pharmaceuticals as Head of Business and Corporate Development

LEXINGTON, Mass.--(Healthcare Sales & Marketing Network)--CoNCERT Pharmaceuticals, Inc. today announced that Gregory L. Miller has joined the company as its new Head of Business and Corporate Development. In this role, Greg will focus on leading Concert’s business development efforts and play a key part in strategic planning initiatives.

“We are very pleased to welcome Greg to Concert,” said Roger Tung, Ph.D., President and Chief Executive Officer of CoNCERT Pharmaceuticals. “His depth and expertise in analysis and business development will be a great asset as we assess, prioritize, and expand our opportunities in strategic partnering for our rapidly growing product pipeline.”

Mr. Miller has broad experience in business and corporate development in the biotechnology industry. Most recently he served as Senior Director, Business Development and Corporate Strategy at AMAG Pharmaceuticals. Prior to joining AMAG, Mr. Miller held a variety of analytical and leadership roles in the corporate development group at Genzyme Corporation. Before joining the biotechnology industry, Mr. Miller has held positions focused on epidemiology and clinical research.

Mr. Miller received a B.A. in Psychology from Brandeis University, was a Harris Fellow at Yale University, and earned a Master of Public Health in Epidemiology and Biostatistics and an MBA from Boston University.

About Concert

CoNCERT Pharmaceuticals is a clinical stage biotechnology company focused on applying the company’s DCE Platform™ to create novel and differentiated small molecule drugs containing deuterium. Concert’s approach leverages known activity and safety of existing drugs to reduce time, risk and expense of drug research and development. The Company has a broad research pipeline encompassing many therapeutic areas including infectious disease and renal disease, among others. In 2009, Concert entered into a potential $1 billion strategic alliance with GlaxoSmithKline to develop and commercialize certain deuterium-containing medicines. Founded in 2006, Concert has raised more than $110 million of venture and institutional capital. For more information on CoNCERT Pharmaceuticals, please visit

CoNCERT Pharmaceuticals, the CoNCERT logo and the DCE Platform are trademarks of CoNCERT Pharmaceuticals, Inc.

Source: Concert Pharmaceuticals

Issuer of this News Release is solely responsible for its content.
Please address inquiries directly to the issuing company.

FindReps - Find Great Medical Independent Sales Reps without recruiter fees.
FindReps - available on the Apple App Store for iPhone and iPad.